Institutional Inflows and Outflows Several large investors have recently modified their holdings of the business. Vanguard Group Inc. increased its position in shares of Acer Therapeutics by 55.5% during the first quarter. Vanguard Group Inc. now owns 278,215 shares of the biopharmaceutical company’s stock worth $807,000 after purchasing an additional 99,335 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Acer Therapeutics by 216.8% during the 2nd quarter. Renaissance Technologies LLC now owns 69,700 shares of the biopharmaceutical company’s stock worth $88,000 after purchasing an additional 47,700 shares during the last quarter. Finally, Copperwynd Financial LLC acquired a new stake in Acer Therapeutics in the 2nd quarter valued at about $29,000. Hedge funds and other institutional investors own 9.76% of the company’s stock.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.